Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1390285 | 0.84 | GPBAR1 (0.53) | ALDH1A1SMN1; SMN2SRD5A2RXRARXRB | |
| SCHEMBL363503 | 0.84 | GPBAR1 (0.53) | ALDH1A1SMN1; SMN2SRD5A2RXRARXRB | |
| SCHEMBL1390580 | 0.83 | GPBAR1 (0.52) | ALDH1A1SMN1; SMN2SRD5A2RXRARXRB | |
| SCHEMBL1395398 | 0.82 | TDP1 (0.43) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL362624 | 0.77 | TDP1 (0.56) | — | |
| Lithium Ion SCHEMBL363471 | 0.75 | GPBAR1 (0.44) | ALDH1A1SMN1; SMN2UTS2R | |
| SCHEMBL15949106 | 0.73 | KMT2A (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL13496178 | 0.73 | FAAH (0.38) | UTS2RALOX5FFAR1 | |
| SCHEMBL13888048 | 0.72 | ALDH1A1 (0.85) | ALDH1A1SMN1; SMN2SRD5A2RXRARXRB | |
| SCHEMBL308875 | 0.72 | ALDH1A1 (0.85) | ALDH1A1SMN1; SMN2SRD5A2RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | ALDH1A1 132/4885SMN1; SMN2 2264/4885SRD5A2 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.